Healthcare shares split as clinical progress meets cash pressure

• AdAlta and Skin Elements were the week’s weakest movers, each falling 33.33%.
• Mesoblast rose 27.32% after higher Ryoncil revenue and a possible FDA filing for a heart-failure treatment.
• Lumos fell 27.71% despite wider US use of FebriDx, as paediatric enrolment slowed and a Hologic timeline moved out.
• Cash remains a central issue, with AdAlta, Chimeric, Nexalis and Cann Group holding less than one quarter of reported funding.